FIELD: medicine.
SUBSTANCE: declared invention refers to medicine. The anti-tuberculosis preparations are cancelled, while Ursosal 20 mg/kg is single administered per os, and Enterosgel 10-15 g for 3 days. Then, a dose of Ursosan is reduced to 12-15 mg/kg a day with underlying reinitiation of the anti-tuberculosis preparations, and the Ursosan therapy is continued until the ALT value appears to be below an upper limit of normal.
EFFECT: method under invention enables higher clinical effectiveness in the drug-induced liver injury in children.
1 tbl, 3 dwg, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF TREATING PATIENTS SUFFERING PULMONARY TUBERCULOSIS | 2011 |
|
RU2456006C1 |
METHOD OF TREATING PARVOVIRAL INFECTION B19 IN INFANTS | 2012 |
|
RU2487708C1 |
HEPATOPROTECTIVE HERBAL TEA | 2012 |
|
RU2500418C1 |
METHOD OF TREATING CHILDREN AND ADOLESCENTS SUFFERING BILE PASSAGE DYSFUNCTION AND LIVING IN ENVIRONMENTALLY UNFRIENDLY REGIONS | 2012 |
|
RU2489152C1 |
METHOD OF TREATING CONJUGATION HYPERBILIRUBINEMIA IN INFANTS | 2014 |
|
RU2570479C1 |
METHOD OF TREATING PATIENTS WITH TUBERCULOUS EXUDATIVE PLEURITIS | 2012 |
|
RU2491089C1 |
METHOD OF TREATING CHILDREN WITH MANIFESTATION OF LINGERING JAUNDICE IN NEONATAL PERIOD | 2009 |
|
RU2432938C2 |
METHOD OF DIFFERENTIAL DIAGNOSTICS OF FORM OF ERECTILE DYSFUNCTION | 2011 |
|
RU2460462C1 |
METHOD OF TREATING PATIENTS SUFFERING FROM FIRST STAGE CHOLELITHIASIS | 2012 |
|
RU2519198C2 |
METHOD FOR PREVENTING AND TREATING HEPATIC CONSEQUENCES OF ISCHEMIA | 2011 |
|
RU2456678C1 |
Authors
Dates
2013-01-27—Published
2011-07-18—Filed